A Pilot Phase II Study of Maintenance Cabozantinib Plus Pembrolizumab for Patients With Metastatic Squamous Non-Small Cell Lung Cancer (sqNSCLC) (LUNG-IST-127)
LUNG-IST-127: A Pilot Phase II Study of Maintenance Cabozantinib Plus Pembrolizumab (CP) for Patients With Metastatic sqNSCLC With Disease Control Following Induction Therapy
Sponsor: University of Illinois at Chicago
Listed as NCT05613413, this PHASE2 trial focuses on Metastatic Squamous Non-Small Cell Lung Carcinoma and remains actively recruiting participants. Sponsored by University of Illinois at Chicago, it has been updated 10 times since 2022, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
10 versions recorded-
Feb 2026 — Present [monthly]
Recruiting PHASE2
-
Mar 2025 — Feb 2026 [monthly]
Recruiting PHASE2
-
Sep 2024 — Mar 2025 [monthly]
Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE2
-
Jan 2024 — Jul 2024 [monthly]
Recruiting PHASE2
▶ Show 5 earlier versions
-
Oct 2023 — Jan 2024 [monthly]
Recruiting PHASE2
-
Apr 2023 — Oct 2023 [monthly]
Recruiting PHASE2
-
Feb 2023 — Apr 2023 [monthly]
Recruiting PHASE2
-
Jan 2023 — Feb 2023 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Dec 2022 — Jan 2023 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- University of Illinois at Chicago
For direct contact, visit the study record on ClinicalTrials.gov .